ID   L-428
AC   CVCL_1361
SY   L 428; L428
DR   BTO; BTO:0000406
DR   CLO; CLO_0007189
DR   EFO; EFO_0002225
DR   CLDB; cl3081
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473371
DR   BioSample; SAMN10988569
DR   cancercelllines; CVCL_1361
DR   Cell_Model_Passport; SIDM00327
DR   ChEMBL-Cells; CHEMBL3308873
DR   ChEMBL-Targets; CHEMBL2366233
DR   CLS; 300200
DR   Cosmic; 850218
DR   Cosmic; 907322
DR   Cosmic; 988703
DR   Cosmic; 1013907
DR   Cosmic; 1086358
DR   Cosmic; 1278830
DR   Cosmic; 1289698
DR   Cosmic; 1432036
DR   Cosmic; 1714161
DR   Cosmic; 2276326
DR   Cosmic; 2361389
DR   Cosmic; 2464304
DR   Cosmic; 2804876
DR   Cosmic-CLP; 907322
DR   DepMap; ACH-000754
DR   DSMZ; ACC-197
DR   DSMZCellDive; ACC-197
DR   EGA; EGAS00001000978
DR   GDSC; 907322
DR   GEO; GSM499721
DR   GEO; GSM499729
DR   GEO; GSM552447
DR   GEO; GSM637988
DR   GEO; GSM887260
DR   GEO; GSM888335
DR   GEO; GSM1670029
DR   IARC_TP53; 21455
DR   IARC_TP53; 23612
DR   IGRhCellID; L428
DR   LiGeA; CCLE_448
DR   LINCS_LDP; LCL-2011
DR   Lonza; 924
DR   PharmacoDB; L428_815_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1361
DR   PubChem_Cell_line; CVCL_1361
DR   Wikidata; Q54900867
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2690233;
RX   PubMed=2898211;
RX   PubMed=3713248;
RX   PubMed=6303739;
RX   PubMed=6305805;
RX   PubMed=7216541;
RX   PubMed=7276066;
RX   PubMed=8547074;
RX   PubMed=8558920;
RX   PubMed=9685479;
RX   PubMed=9787181;
RX   PubMed=11021758;
RX   PubMed=12133989;
RX   PubMed=17065008;
RX   PubMed=19380639;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20628145;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 42-46 hours (PubMed=7216541); ~35 hours (DSMZ=ACC-197).
CC   HLA typing: A*03:01; B*35:03; C*04:01/03/05/07; DQB1*03:01/09; DRB1*12:01/06; DRB3*02 (PubMed=12133989).
CC   HLA typing: A*03:01,03:01; B*35:03,35:03; C*04:01,04:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*03:17,12:01 (PubMed=26589293).
CC   HLA typing: A*03:01:01,03:01:01; B*35:03:01,35:03:01; C*04:01:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRA*01:02:02,01:02:02; DRB1*12:01:01,12:01:01 (DSMZCellDive=ACC-197).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly112_Val122del11 (c.334_366del33); Zygosity=Heterozygous (PubMed=17065008; Cosmic-CLP).
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=2.16%; Native American=0%; East Asian, North=3.23%; East Asian, South=0%; South Asian=0%; European, North=65.81%; European, South=28.79% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 14
ST   D16S539: 11,12
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 31.2
ST   D2S1338: 17,19
ST   D3S1358: 14,18
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 14
ST   FGA: 19,25,26
ST   Penta D: 8,9
ST   Penta E: 10,17
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2690233; DOI=10.1007/978-3-642-83781-4_5;
RA   Schaadt M., Burrichter H., Pfreundschuh M., Schell-Frederick E.,
RA   Tesch H., Fonatsch C., Stein H., Diehl V.;
RT   "Biology of Hodgkin cell lines.";
RL   Recent Results Cancer Res. 117:53-61(1989).
//
RX   PubMed=2898211;
RA   Newcom S.R., Kadin M.E., Ansari A.A.;
RT   "Production of transforming growth factor-beta activity by Ki-1
RT   positive lymphoma cells and analysis of its role in the regulation of
RT   Ki-1 positive lymphoma growth.";
RL   Am. J. Pathol. 131:569-577(1988).
//
RX   PubMed=3713248; DOI=10.1016/0145-2126(86)90084-6;
RA   Drexler H.G., Gaedicke G., Lok M.-S., Diehl V., Minowada J.;
RT   "Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of
RT   morphology, immunological and isoenzyme profiles.";
RL   Leuk. Res. 10:487-500(1986).
//
RX   PubMed=6303739; DOI=10.1055/s-2008-1069671;
RA   Kirchner H.H., Burrichter H., Stein H., Fonatsch C., Schaadt M.,
RA   Ziegler A., Heit W., Diehl V.;
RT   "Properties of Hodgkin cell lines. Possible significance for
RT   pathophysiology and clinical medicine.";
RL   Dtsch. Med. Wochenschr. 108:936-944(1983).
//
RX   PubMed=6305805; DOI=10.1007/978-3-642-68761-7_81;
RA   Diehl V., Burrichter H., Schaadt M., Kirchner H.H., Fonatsch C.,
RA   Stein H., Gerdes J., Heit W., Ziegler A.;
RT   "Hodgkin's disease cell lines: characteristics and biological
RT   activities.";
RL   Haematol. Blood Transfus. 28:411-417(1983).
//
RX   PubMed=7216541; DOI=10.1002/ijc.2910260605;
RA   Schaadt M., Diehl V., Stein H., Fonatsch C., Kirchner H.H.;
RT   "Two neoplastic cell lines with unique features derived from Hodgkin's
RT   disease.";
RL   Int. J. Cancer 26:723-731(1980).
//
RX   PubMed=7276066; DOI=10.1007/BF00405072;
RA   Diehl V., Kirchner H.H., Schaadt M., Fonatsch C., Stein H., Gerdes J.,
RA   Boie C.;
RT   "Hodgkin's disease: establishment and characterization of four in
RT   vitro cell lines.";
RL   J. Cancer Res. Clin. Oncol. 101:111-124(1981).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=12133989; DOI=10.4049/jimmunol.169.3.1593;
RA   Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K.,
RA   Hanekom W.A., Fonteneau J.-F., Stevanovic S., Munz C.;
RT   "Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill
RT   Burkitt's lymphoma cells.";
RL   J. Immunol. 169:1593-1603(2002).
//
RX   PubMed=17065008; DOI=10.1080/10428190600667721;
RA   Feuerborn A., Moritz C., von Bonin F., Dobbelstein M., Trumper L.,
RA   Sturzenhofecker B., Kube D.;
RT   "Dysfunctional p53 deletion mutants in cell lines derived from
RT   Hodgkin's lymphoma.";
RL   Leuk. Lymphoma 47:1932-1940(2006).
//
RX   PubMed=19380639; DOI=10.1084/jem.20090528;
RA   Schmitz R., Hansmann M.-L., Bohle V., Martin-Subero J.I., Hartmann S.,
RA   Mechtersheimer G., Klapper W., Vater I., Giefing M., Gesk S.,
RA   Stanelle J., Siebert R., Kuppers R.;
RT   "TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and
RT   primary mediastinal B cell lymphoma.";
RL   J. Exp. Med. 206:981-989(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//